High levels of TSP1+/CD142+ platelet-derived microparticles characterise young patients with high cardiovascular risk and subclinical atherosclerosis

Thrombosis and Haemostasis

Volumn 114, Issue 6, 2015, Pages 1310-1321

  Suades, Rosa ^a   Padró, Teresa ^a   Alonso, Rodrigo ^b   Mata, Pedro ^b   Badimon, Lina ^a,c  

^a Institut Català de Ciències Cardiovasculars   (Spain)

^b Medicina Interna   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Atherothrombosis; Circulating microparticles; Platelets; Risk factors; Tissue factor

Indexed keywords

CD142 ANTIGEN; LYMPHOCYTE ANTIGEN; THROMBOSPONDIN 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; LIPID; THROMBOPLASTIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MEMBRANE MICROPARTICLE; NUCLEAR MAGNETIC RESONANCE IMAGING; PLATELET MICROPARTICLE; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; AGE; AORTIC DISEASES; ASYMPTOMATIC DISEASE; BLOOD; CALCINOSIS; CARDIOVASCULAR DISEASES; CHEMISTRY; COHORT ANALYSIS; COMPARATIVE STUDY; COMPLICATION; FAMILIAL HYPERCHOLESTEROLEMIA; GENETICS; HETEROZYGOTE; HYPERCHOLESTEROLEMIA; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; RISK FACTOR; THORACIC AORTA; THROMBOCYTE; ULTRASTRUCTURE;

AGE FACTORS; AORTA, THORACIC; AORTIC DISEASES; ASYMPTOMATIC DISEASES; BIOMARKERS; BLOOD PLATELETS; CALCINOSIS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; COHORT STUDIES; FEMALE; HETEROZYGOTE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPOPROTEINEMIA TYPE II; LIPIDS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; PLATELET ACTIVATION; RISK FACTORS; THROMBOPLASTIN; THROMBOSPONDIN 1;

EID: 84983132667     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-04-0325     Document Type: Article

References (50)

1. Hovingh GK, Davidson MH, Kastelein JJ, et al. Diagnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013; 34: 962-971.
2. Neefjes LA, Ten Kate GJ, Alexia R, et al. Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolaemia. Atherosclerosis 2011; 219: 721-727.
3. Gill PJ, Harnden A, Karpe F. Familial hypercholesterolaemia. Br Med J 2012; 344: e3228.
4. Caballero P, Alonso R, Rosado P, et al. Detection of subclinical atherosclerosis in familial hypercholesterolaemia using non-invasive imaging modalities. Atherosclerosis 2012; 222: 468-472.
5. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-599.
6. Fernandez-Ortiz A, Badimon JJ, Falk E, et al. Characterisation of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-1569.
7. Badimon L, Storey RF, Vilahur G. Update on lipids, inflammation and atherothrombosis. Thromb Haemost 2011; 105 (Suppl 1): S34-42.
8. Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, et al. Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells. Circulation 2004; 110: 452-459.
9. Boulanger CM. Microparticles, vascular function and hypertension. Curr Opin Nephrol Hypertens 2010; 19: 177-180.
10. Berckmans RJ, Nieuwland R, Boing AN, et al. Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation. Thromb Haemost 2001; 85: 639-646.
11. Koga H, Sugiyama S, Kugiyama K, et al. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2005; 45: 1622-1630.
12. Suades R, Padro T, Alonso R, et al. Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in FH patients. Thromb Haemost 2014; 111: 111-121.
13. Sinning JM, Losch J, Walenta K, et al. Circulating CD31+/Annexin V+ microparticles correlate with cardiovascular outcomes. Eur Heart J 2010; 32: 2034-2041.
14. Mata N, Alonso R, Badimon L, et al. Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolaemia Longitudinal Cohort Study (SAFEHEART). Lipids Health Dis 2011; 10: 94.
15. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
16. Wierzbicki AS, Humphries SE, Minhas R. Familial hypercholesterolaemia: summary of NICE guidance. Br Med J 2008; 337: a1095.
17. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-1818.
18. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolaemia: a large cross-sectional study in The Netherlands. Atherosclerosis 2010; 209: 189-194.
19. Gehi AK, Ali S, Na B, et al. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Arch Intern Med 2007; 167: 1798-1803.
20. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
21. Mozas P, Castillo S, Tejedor D, et al. Molecular characterisation of familial hypercholesterolaemia in Spain: identification of 39 novel and 77 recurrent mutations in LDLR. Hum Mutat 2004; 24: 187.
22. Suades R, Padro T, Alonso R, et al. Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells. Thromb Haemost 2013; 110: 366-377.
23. Corti R, Fuster V. Imaging of atherosclerosis: magnetic resonance imaging. Eur Heart J 2011; 32: 1709-1719b.
24. Vilades Medel D, Leta Petracca R, Carreras Costa F, et al. Coronary computed tomographic angiographic findings in asymptomatic patients with heterozygous familial hypercholesterolaemia and null allele low-density lipoprotein receptor mutations. Am J Cardiol 2013; 111: 955-961.
25. Teis A, Cadena A, Alomar X, et al. Quadricuspid pulmonic valve: diagnosis by MRI. Eur Heart J Cardiovasc Imaging 2013; 14: 398.
26. Carreras F, Garcia-Barnes J, Gil D, et al. Left ventricular torsion and longitudinal shortening: two fundamental components of myocardial mechanics assessed by tagged cine-MRI in normal subjects. Int J Cardiovasc Imaging 2012; 28: 273-284.
27. Rank A, Liebhardt S, Zwirner J, et al. Circulating microparticles in patients with benign and malignant ovarian tumors. Anticancer Res 2012; 32: 2009-2014.
28. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 1983; 148: 839-843.
29. Loyer X, Vion AC, Tedgui A, et al. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res 2014; 114: 345-353.
30. Hristov M, Weber C. Differential role of monocyte subsets in atherosclerosis. Thromb Haemost 2011; 106: 757-762.
31. Rogacev KS, Cremers B, Zawada AM, et al. CD14++CD16+ monocytes independently predict cardiovascular events: a cohort study of 951 patients referred for elective coronary angiography. J Am Coll Cardiol 2012; 60: 1512-1520.
32. Krychtiuk KA, Kastl SP, Pfaffenberger S, et al. Association of Small Dense LDL Serum Levels and Circulating Monocyte Subsets in Stable Coronary Artery Disease. PLoS One 2015; 10: e0123367.
33. Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med 2014; 276: 618-632.
34. Chen K, Li W, Major J, et al. Vav guanine nucleotide exchange factors link hyperlipidemia and a prothrombotic state. Blood 2011; 117: 5744-5750.
35. Nomura S, Tandon NN, Nakamura T, et al. High-shear-stress-induced activation of platelets and microparticles enhances expression of cell adhesion molecules in THP-1 and endothelial cells. Atherosclerosis 2001; 158: 277-287.
36. Suades R, Padro T, Vilahur G, et al. Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques. Thromb Haemost 2012; 108: 1208-1219.
37. Van Der Meijden PE, Van Schilfgaarde M, Van Oerle R, et al. Platelet-and erythrocyte-derived microparticles trigger thrombin generation via factor XIIa. J Thromb Haemost 2012; 10: 1355-1362.
38. Forlow SB, McEver RP, Nollert MU. Leukocyte-leukocyte interactions mediated by platelet microparticles under flow. Blood 2000; 95: 1317-1323.
39. Butenas S, Bouchard BA, Brummel-Ziedins KE, et al. Tissue factor activity in whole blood. Blood 2005; 105: 2764-2770.
40. Camera M, Brambilla M, Toschi V, et al. Tissue factor expression on platelets is a dynamic event. Blood 2010; 116: 5076-5077.
41. Osterud B, Bjorklid E. Sources of tissue factor. Semin Thromb Hemost 2006; 32: 11-23.
42. Camera M, Brambilla M, Facchinetti L, et al. Tissue factor and atherosclerosis: not only vessel wall-derived TF, but also platelet-associated TF. Thromb Res 2012; 129: 279-284.
43. Del Conde I, Shrimpton CN, Thiagarajan P, et al. Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. Blood 2005; 106: 1604-1611.
44. Nieuwland R. Cellular origin of microparticles exposing tissue factor in cancer: a mixed double? J Thromb Haemost 2008; 6: 1514-1516.
45. Aberg M, Siegbahn A. Tissue factor non-coagulant signaling-molecular mechanisms and biological consequences with a focus on cell migration and apoptosis. J Thromb Haemost 2013; 11: 817-825.
46. Kleinjan A, Boing AN, Sturk A, et al. Microparticles in vascular disorders: how tissue factor-exposing vesicles contribute to pathology and physiology. Thromb Res 2012; 130 (Suppl 1): S71-73.
47. Owens AP, 3rd, Passam FH, Antoniak S, et al. Monocyte tissue factor-dependent activation of coagulation in hypercholesterolaemic mice and monkeys is inhibited by simvastatin. J Clin Invest 2012; 122: 558-568.
48. Jayachandran M, Litwiller RD, Owen WG, et al. Characterisation of blood borne microparticles as markers of premature coronary calcification in newly menopausal women. Am J Physiol Heart Circ Physiol 2008; 295: H931-H938.
49. Del Turco S, Basta G, Mazzarisi A, et al. Procoagulant activity of circulating microparticles is associated with the presence of moderate calcified plaque burden detected by multislice computed tomography. J Geriatr Cardiol 2014; 11: 13-19.
50. Mause SF. Platelet microparticles: reinforcing the hegemony of platelets in atherothrombosis. Thromb Haemost 2012; 109: 5-6.